An international research-oriented biopharmaceutical group, with over 85 years of experience. Headquartered in Parma, Italy, Chiesi continues to be a family-owned business, which export to more than 100 countries, with a direct presence in 31. The Chiesi Group researches, develops and innovates therapeutic solutions in respiratory health, rare diseases, and specialty care.

Chiesi Australia is the Australia-New Zealand division of the Chiesi Group, formed following the acquisition of Emerge Health in November 2019. Since acquiring Emerge Health, Chiesi Australia & New Zealand has been actively collaborating with local stakeholders to introduce innovative medicines. The company focuses on respiratory medicine, specialty care through international in-licensing partnerships, and more recently, expanding its portfolio to support Australians living with rare diseases.

Chiesi’s commitment to patients in Australia and New Zealand is demonstrated through ongoing engagement and investment in local patient advocacy, scientific societies, and peak healthcare bodies. By fostering these vital partnerships, Chiesi ensures Australian and New Zealand patients are well-represented in the global healthcare landscape.

Throughout 2026, 120 Chiesi staff will have the opportunity to undertake corporate environmental volunteering, where staff will support local groups to deliver on their important work programs.